
open access
메뉴
E-ISSN : 2671-6771
Exon-level copy-number analysis followed by sequencing of all 79 DMD exons and their flanking intronic sequence achieves a cumulative sensitivity approaching 99%, and no current protocol reaches 100% sensitivity. In clinical series, however, approximately 2–5% of patients with convincing dystrophinopathy remain molecularly unresolved after such testing. This review addresses that residual group. The reasons for failure lie in the architecture of the locus: more than 99% of the 2.22 Mb locus is intronic, dosage-based assays cannot detect balanced rearrangements, and short reads resolve repeat-embedded breakpoints poorly. Published studies identify two main categories — deep intronic splice-altering variants and complex structural variants — but their relative proportions across populations remain uncertain. The evidence required to classify such a variant as causative depends on its class: transcript analysis is effectively indispensable for a novel deep intronic variant, whereas a rearrangement that directly disrupts coding exons may be resolved from breakpoint, phenotype and dystrophin findings. I set out how splicing evidence enters classification under the ClinGen Sequence Variant Interpretation Splicing Subgroup recommendations, a stage at which the same RNA result can inadvertently be counted twice. I also set out how the evidence for a balanced structural variant must be assembled where neither the copy-number nor the splicing scoring framework covers it, and propose a staged approach to the unresolved patient. Resolving the variant is a precondition for assessing genotype-dependent therapeutic eligibility and for variant-specific carrier testing in the family.